Objective: Antidepressant medication is efficacious in the treatment of depression, but not all patients improve with antidepressant medication alone. Despite this treatment gap, limited evidence regarding the effectiveness of supplementing psychotherapy for pharmacotherapy-resistant depression is available. Therefore, we investigated the effectiveness of supplementing usual medication management (treatment as usual [TAU]) with cognitive-behavioral therapy (CBT) in patients with pharmacotherapy-resistant depression seeking psychiatric specialty care.
Methods: A 16-week assessor-masked randomized controlled trial with a 12-month follow-up was conducted in 1 university hospital and 1 psychiatric hospital from September 2008 to December 2014. Outpatients aged 20-65 years with pharmacotherapy-resistant depression (taking antidepressant medications for ≥ 8 weeks, 17-item GRID-Hamilton Depression Rating Scale [GRID-HDRS₁₇] score ≥ 16, Maudsley Staging Method for treatment-resistant depression score ≥ 3, and DSM-IV criteria for major depressive disorder) were randomly assigned (1:1) to CBT combined with TAU or to TAU alone. The primary outcome was the alleviation of depressive symptoms, as measured by change in the total GRID-HDRS₁₇ score from baseline to 16 weeks; primary analysis was done on an intention-to-treat basis.
Results: A total of 80 patients were randomized; 78 (97.5%) were assessed for the primary outcome, and 73 (91.3%) were followed up for 12 months. Supplementary CBT significantly alleviated depressive symptoms at 16 weeks, as shown by greater least squares mean changes in GRID-HDRS₁₇ scores in the intervention group than in the control group (-12.7 vs -7.4; difference = -5.4; 95% CI, -8.1 to -2.6; P < .001), and the treatment effect was maintained for at least 12 months (-15.4 vs -11.0; difference = -4.4; 95% CI, -7.2 to -1.6; P = .002).
Conclusions: Patients with pharmacotherapy-resistant depression treated in psychiatric specialty care settings may benefit from supplementing usual medication management with CBT.
Trial Registration: UMIN Clinical Trials Registry identifier: UMIN000001218.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/JCP.15m10511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurobiological mechanisms of electroconvulsive therapy for depression: Insights into hippocampal volumetric increases from clinical and preclinical studies.
J Neurochem
September 2024
Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Depression is a highly prevalent and disabling psychiatric disorder. The hippocampus, which plays a central role in mood regulation and memory, has received considerable attention in depression research. Electroconvulsive therapy (ECT) is the most effective treatment for severe pharmacotherapy-resistant depression.
View Article and Find Full Text PDFDepression in dementia with Lewy bodies: a critical update.
J Neural Transm (Vienna)
October 2023
Institute of Clinical Neurobiology, Alberichgasse 5/13, 1150, Vienna, Austria.
Depression with an estimated prevalence of 35% is a frequent manifestation of dementia with Lewy bodies (DLB), having negative effects on cognitive performance and life expectancy, yet the underlying neurobiology is poorly understood and most likely heterogeneous. Depressive symptoms in DLB can occur during the clinical course and, together with apathy, is a common prodromal neuropsychiatric symptom of this neurocognitive disorder in the group of Lewy body synucleinopathies. There are no essential differences in the frequency of depression in DLB and Parkinson disease-dementia (PDD), while its severity is up to twice as high as in Alzheimer disease (AD).
View Article and Find Full Text PDFA Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression.
Neuropsychiatr Dis Treat
November 2022
Department of Psychiatry, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Article Synopsis
- - The text discusses the lack of a universal definition for treatment-resistant depression (TRD) in Southeast Asia, demonstrating the need for a standardized approach to its management across the region.
- - A panel of 13 psychiatrists developed a new term, "pharmacotherapy-resistant depression" (PRD), defining it as the failure of two adequate drug treatments during a major depressive episode, and outlined a stepwise treatment plan including medication adjustments and non-pharmacological options.
- - The consensus recommendations can be adapted to different Southeast Asian contexts, but the importance of clinical judgment and individual patient circumstances in treatment decisions remains emphasized.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!